Randomised, double‐blind, placebo‐controlled trial to assess the potential of cannabinoid receptor stimulation in the treatment of dystonia
Identifieur interne : 003166 ( Istex/Curation ); précédent : 003165; suivant : 003167Randomised, double‐blind, placebo‐controlled trial to assess the potential of cannabinoid receptor stimulation in the treatment of dystonia
Auteurs : Susan H. Fox [Royaume-Uni] ; Mark Kellett [Royaume-Uni] ; A. Peter Moore [Royaume-Uni] ; Alan R. Crossman [Royaume-Uni] ; Jonathan M. Brotchie [Royaume-Uni]Source :
- Movement Disorders [ 0885-3185 ] ; 2002-01.
English descriptors
- KwdEn :
Abstract
Cannabis may have medicinal uses in a variety of diseases. The neural mechanisms underlying dystonia involve abnormalities within the basal ganglia—in particular, overactivity of the lateral globus pallidus (GPl). Cannabinoid receptors are located presynaptically on GABA terminals within the GPi, where their activation reduces GABA reuptake. Cannabinoid receptor stimulation may thus reduce overactivity of the GPl and thereby reduce dystonia. A double‐blind, randomised, placebo‐controlled, crossover study using the synthetic cannabinoid receptor agonist nabilone in patients with generalised and segmental primary dystonia showed no significant reduction in dystonia following treatment with nabilone. © 2001 Movement Disorder Society.
Url:
DOI: 10.1002/mds.1280
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: Pour aller vers cette notice dans l'étape Curation :003166
Links to Exploration step
ISTEX:820A66911789DED586603BDE2C38BCABB5D36D7CLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Randomised, double‐blind, placebo‐controlled trial to assess the potential of cannabinoid receptor stimulation in the treatment of dystonia</title>
<author><name sortKey="Fox, Susan H" sort="Fox, Susan H" uniqKey="Fox S" first="Susan H." last="Fox">Susan H. Fox</name>
<affiliation wicri:level="1"><mods:affiliation>Walton Centre for Neurology and Neurosurgery, Liverpool, United Kingdom</mods:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Walton Centre for Neurology and Neurosurgery, Liverpool</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Kellett, Mark" sort="Kellett, Mark" uniqKey="Kellett M" first="Mark" last="Kellett">Mark Kellett</name>
<affiliation wicri:level="1"><mods:affiliation>Walton Centre for Neurology and Neurosurgery, Liverpool, United Kingdom</mods:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Walton Centre for Neurology and Neurosurgery, Liverpool</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1"><mods:affiliation>Current Address: Department of Neurology, Hope Hospital, Stott Lane, Salford, Manchester M6 7HD, UK</mods:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Current Address: Department of Neurology, Hope Hospital, Stott Lane, Salford, Manchester M6 7HD</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Moore, A Peter" sort="Moore, A Peter" uniqKey="Moore A" first="A. Peter" last="Moore">A. Peter Moore</name>
<affiliation wicri:level="1"><mods:affiliation>Walton Centre for Neurology and Neurosurgery, Liverpool, United Kingdom</mods:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Walton Centre for Neurology and Neurosurgery, Liverpool</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Crossman, Alan R" sort="Crossman, Alan R" uniqKey="Crossman A" first="Alan R." last="Crossman">Alan R. Crossman</name>
<affiliation wicri:level="1"><mods:affiliation>Manchester Movement Disorders Laboratory, Division of Neuroscience, School of Biological Sciences, University of Manchester, and Motac Neuroscience Ltd., Manchester Incubator Building, Manchester, United Kingdom</mods:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Manchester Movement Disorders Laboratory, Division of Neuroscience, School of Biological Sciences, University of Manchester, and Motac Neuroscience Ltd., Manchester Incubator Building, Manchester</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Brotchie, Jonathan M" sort="Brotchie, Jonathan M" uniqKey="Brotchie J" first="Jonathan M." last="Brotchie">Jonathan M. Brotchie</name>
<affiliation wicri:level="1"><mods:affiliation>Manchester Movement Disorders Laboratory, Division of Neuroscience, School of Biological Sciences, University of Manchester, and Motac Neuroscience Ltd., Manchester Incubator Building, Manchester, United Kingdom</mods:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Manchester Movement Disorders Laboratory, Division of Neuroscience, School of Biological Sciences, University of Manchester, and Motac Neuroscience Ltd., Manchester Incubator Building, Manchester</wicri:regionArea>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:820A66911789DED586603BDE2C38BCABB5D36D7C</idno>
<date when="2002" year="2002">2002</date>
<idno type="doi">10.1002/mds.1280</idno>
<idno type="url">https://api.istex.fr/document/820A66911789DED586603BDE2C38BCABB5D36D7C/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">003166</idno>
<idno type="wicri:Area/Istex/Curation">003166</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Randomised, double‐blind, placebo‐controlled trial to assess the potential of cannabinoid receptor stimulation in the treatment of dystonia</title>
<author><name sortKey="Fox, Susan H" sort="Fox, Susan H" uniqKey="Fox S" first="Susan H." last="Fox">Susan H. Fox</name>
<affiliation wicri:level="1"><mods:affiliation>Walton Centre for Neurology and Neurosurgery, Liverpool, United Kingdom</mods:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Walton Centre for Neurology and Neurosurgery, Liverpool</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Kellett, Mark" sort="Kellett, Mark" uniqKey="Kellett M" first="Mark" last="Kellett">Mark Kellett</name>
<affiliation wicri:level="1"><mods:affiliation>Walton Centre for Neurology and Neurosurgery, Liverpool, United Kingdom</mods:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Walton Centre for Neurology and Neurosurgery, Liverpool</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1"><mods:affiliation>Current Address: Department of Neurology, Hope Hospital, Stott Lane, Salford, Manchester M6 7HD, UK</mods:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Current Address: Department of Neurology, Hope Hospital, Stott Lane, Salford, Manchester M6 7HD</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Moore, A Peter" sort="Moore, A Peter" uniqKey="Moore A" first="A. Peter" last="Moore">A. Peter Moore</name>
<affiliation wicri:level="1"><mods:affiliation>Walton Centre for Neurology and Neurosurgery, Liverpool, United Kingdom</mods:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Walton Centre for Neurology and Neurosurgery, Liverpool</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Crossman, Alan R" sort="Crossman, Alan R" uniqKey="Crossman A" first="Alan R." last="Crossman">Alan R. Crossman</name>
<affiliation wicri:level="1"><mods:affiliation>Manchester Movement Disorders Laboratory, Division of Neuroscience, School of Biological Sciences, University of Manchester, and Motac Neuroscience Ltd., Manchester Incubator Building, Manchester, United Kingdom</mods:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Manchester Movement Disorders Laboratory, Division of Neuroscience, School of Biological Sciences, University of Manchester, and Motac Neuroscience Ltd., Manchester Incubator Building, Manchester</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Brotchie, Jonathan M" sort="Brotchie, Jonathan M" uniqKey="Brotchie J" first="Jonathan M." last="Brotchie">Jonathan M. Brotchie</name>
<affiliation wicri:level="1"><mods:affiliation>Manchester Movement Disorders Laboratory, Division of Neuroscience, School of Biological Sciences, University of Manchester, and Motac Neuroscience Ltd., Manchester Incubator Building, Manchester, United Kingdom</mods:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Manchester Movement Disorders Laboratory, Division of Neuroscience, School of Biological Sciences, University of Manchester, and Motac Neuroscience Ltd., Manchester Incubator Building, Manchester</wicri:regionArea>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>John Wiley & Sons, Inc.</publisher>
<pubPlace>New York</pubPlace>
<date type="published" when="2002-01">2002-01</date>
<biblScope unit="vol">17</biblScope>
<biblScope unit="issue">1</biblScope>
<biblScope unit="page" from="145">145</biblScope>
<biblScope unit="page" to="149">149</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">820A66911789DED586603BDE2C38BCABB5D36D7C</idno>
<idno type="DOI">10.1002/mds.1280</idno>
<idno type="ArticleID">MDS1280</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>cannabis</term>
<term>dystonia</term>
<term>globus pallidus</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Cannabis may have medicinal uses in a variety of diseases. The neural mechanisms underlying dystonia involve abnormalities within the basal ganglia—in particular, overactivity of the lateral globus pallidus (GPl). Cannabinoid receptors are located presynaptically on GABA terminals within the GPi, where their activation reduces GABA reuptake. Cannabinoid receptor stimulation may thus reduce overactivity of the GPl and thereby reduce dystonia. A double‐blind, randomised, placebo‐controlled, crossover study using the synthetic cannabinoid receptor agonist nabilone in patients with generalised and segmental primary dystonia showed no significant reduction in dystonia following treatment with nabilone. © 2001 Movement Disorder Society.</div>
</front>
</TEI>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Istex/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003166 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Curation/biblio.hfd -nk 003166 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= MovDisordV3 |flux= Istex |étape= Curation |type= RBID |clé= ISTEX:820A66911789DED586603BDE2C38BCABB5D36D7C |texte= Randomised, double‐blind, placebo‐controlled trial to assess the potential of cannabinoid receptor stimulation in the treatment of dystonia }}
![]() | This area was generated with Dilib version V0.6.23. | ![]() |